Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis

Jeffrey M. Peters, Jennifer E. Foreman, Frank J. Gonzalez

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) is a promising drug target since its agonists increase serum high-density lipoprotein; decrease low-density lipoprotein, triglycerides, and insulin associated with metabolic syndrome; improve insulin sensitivity; and decrease high fat diet-induced obesity. PPARβ/δ agonists also promote terminal differentiation and elicit anti-inflammatory activities in many cell types. However, it remains to be determined whether PPARβ/δ agonists can be developed as therapeutics because there are reports showing either pro- or anti-carcinogenic effects of PPARβ/δ in cancer models. This review examines studies reporting the role of PPARβ/δ in colon, breast, and lung cancers. The prevailing evidence would suggest that targeting PPARβ/δ is not only safe but could have anti-carcinogenic protective effects.

Original languageEnglish (US)
Pages (from-to)619-640
Number of pages22
JournalCancer and Metastasis Reviews
Volume30
Issue number3-4
DOIs
StatePublished - Dec 1 2011

Fingerprint

Peroxisome Proliferator-Activated Receptors
Colon
Carcinogenesis
Breast
Lung
Anticarcinogenic Agents
High Fat Diet
HDL Lipoproteins
Colonic Neoplasms
Insulin Resistance
Lung Neoplasms
Anti-Inflammatory Agents
Obesity
Insulin
Breast Neoplasms
Serum
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{529064c9e19044b9a2fb5fbe01c6e7c3,
title = "Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis",
abstract = "Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) is a promising drug target since its agonists increase serum high-density lipoprotein; decrease low-density lipoprotein, triglycerides, and insulin associated with metabolic syndrome; improve insulin sensitivity; and decrease high fat diet-induced obesity. PPARβ/δ agonists also promote terminal differentiation and elicit anti-inflammatory activities in many cell types. However, it remains to be determined whether PPARβ/δ agonists can be developed as therapeutics because there are reports showing either pro- or anti-carcinogenic effects of PPARβ/δ in cancer models. This review examines studies reporting the role of PPARβ/δ in colon, breast, and lung cancers. The prevailing evidence would suggest that targeting PPARβ/δ is not only safe but could have anti-carcinogenic protective effects.",
author = "Peters, {Jeffrey M.} and Foreman, {Jennifer E.} and Gonzalez, {Frank J.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1007/s10555-011-9320-1",
language = "English (US)",
volume = "30",
pages = "619--640",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "3-4",

}

Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis. / Peters, Jeffrey M.; Foreman, Jennifer E.; Gonzalez, Frank J.

In: Cancer and Metastasis Reviews, Vol. 30, No. 3-4, 01.12.2011, p. 619-640.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis

AU - Peters, Jeffrey M.

AU - Foreman, Jennifer E.

AU - Gonzalez, Frank J.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) is a promising drug target since its agonists increase serum high-density lipoprotein; decrease low-density lipoprotein, triglycerides, and insulin associated with metabolic syndrome; improve insulin sensitivity; and decrease high fat diet-induced obesity. PPARβ/δ agonists also promote terminal differentiation and elicit anti-inflammatory activities in many cell types. However, it remains to be determined whether PPARβ/δ agonists can be developed as therapeutics because there are reports showing either pro- or anti-carcinogenic effects of PPARβ/δ in cancer models. This review examines studies reporting the role of PPARβ/δ in colon, breast, and lung cancers. The prevailing evidence would suggest that targeting PPARβ/δ is not only safe but could have anti-carcinogenic protective effects.

AB - Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) is a promising drug target since its agonists increase serum high-density lipoprotein; decrease low-density lipoprotein, triglycerides, and insulin associated with metabolic syndrome; improve insulin sensitivity; and decrease high fat diet-induced obesity. PPARβ/δ agonists also promote terminal differentiation and elicit anti-inflammatory activities in many cell types. However, it remains to be determined whether PPARβ/δ agonists can be developed as therapeutics because there are reports showing either pro- or anti-carcinogenic effects of PPARβ/δ in cancer models. This review examines studies reporting the role of PPARβ/δ in colon, breast, and lung cancers. The prevailing evidence would suggest that targeting PPARβ/δ is not only safe but could have anti-carcinogenic protective effects.

UR - http://www.scopus.com/inward/record.url?scp=83855160814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83855160814&partnerID=8YFLogxK

U2 - 10.1007/s10555-011-9320-1

DO - 10.1007/s10555-011-9320-1

M3 - Review article

C2 - 22037942

AN - SCOPUS:83855160814

VL - 30

SP - 619

EP - 640

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 3-4

ER -